Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.
Candida
Intra-abdominal infection
Invasive candidiasis
Risk factors
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
29
09
2021
accepted:
14
12
2021
pubmed:
20
2
2022
medline:
20
2
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
Intra-abdominal infections represent the second most frequently acquired infection in the intensive care unit (ICU), with mortality rates ranging from 20% to 50%. Candida spp. may be responsible for up to 10-30% of cases. This study assesses risk factors for development of intra-abdominal candidiasis (IAC) among patients admitted to ICU. We performed a case-control study in 26 European ICUs during the period January 2015-December 2016. Patients at least 18 years old who developed an episode of microbiologically documented IAC during their stay in the ICU (at least 48 h after admission) served as the case cohort. The control group consisted of adult patients who did not develop episodes of IAC during ICU admission. Matching was performed at a ratio of 1:1 according to time at risk (i.e. controls had to have at least the same length of ICU stay as their matched cases prior to IAC onset), ICU ward and period of study. During the study period, 101 case patients with a diagnosis of IAC were included in the study. On univariate analysis, severe hepatic failure, prior receipt of antibiotics, prior receipt of parenteral nutrition, abdominal drain, prior bacterial infection, anastomotic leakage, recurrent gastrointestinal perforation, prior receipt of antifungal drugs and higher median number of abdominal surgical interventions were associated with IAC development. On multivariate analysis, recurrent gastrointestinal perforation (OR 13.90; 95% CI 2.65-72.82, p = 0.002), anastomotic leakage (OR 6.61; 95% CI 1.98-21.99, p = 0.002), abdominal drain (OR 6.58; 95% CI 1.73-25.06, p = 0.006), prior receipt of antifungal drugs (OR 4.26; 95% CI 1.04-17.46, p = 0.04) or antibiotics (OR 3.78; 95% CI 1.32-10.52, p = 0.01) were independently associated with IAC. Gastrointestinal perforation, anastomotic leakage, abdominal drain and prior receipt of antifungals or antibiotics may help to identify critically ill patients with higher probability of developing IAC. Prospective studies are needed to identify which patients will benefit from early antifungal treatment.
Identifiants
pubmed: 35182353
doi: 10.1007/s40121-021-00585-6
pii: 10.1007/s40121-021-00585-6
pmc: PMC8960530
doi:
Types de publication
Journal Article
Langues
eng
Pagination
827-840Informations de copyright
© 2022. The Author(s).
Références
De Waele J, Lipman J, Sakr Y, et al. Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. BMC Infect Dis. 2014;14:420. https://doi.org/10.1186/1471-2334-14-420 .
doi: 10.1186/1471-2334-14-420
pubmed: 25074742
pmcid: 4122779
Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9. https://doi.org/10.1001/jama.2009.1754 .
doi: 10.1001/jama.2009.1754
pubmed: 19952319
Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004;30(4):589–96. https://doi.org/10.1007/s00134-004-2157-0 .
doi: 10.1007/s00134-004-2157-0
pubmed: 14963646
Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O, AmarCand Study Group. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17(7):1061–7. https://doi.org/10.1111/j.1469-0691.2010.03360.x .
doi: 10.1111/j.1469-0691.2010.03360.x
pubmed: 20825438
Blot S, Antonelli M, Arvaniti K, et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med. 2019;45(12):1703–17. https://doi.org/10.1007/s00134-019-05819-3 .
doi: 10.1007/s00134-019-05819-3
pubmed: 31664501
pmcid: 6863788
Augustin P, Kermarrec N, Muller-Serieys C, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care. 2010;14(1):R20. https://doi.org/10.1186/cc8877 .
doi: 10.1186/cc8877
pubmed: 20156360
pmcid: 2875535
Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53(4):408–15. https://doi.org/10.1016/j.ijantimicag.2018.11.001 .
doi: 10.1016/j.ijantimicag.2018.11.001
pubmed: 30415002
Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9:37. https://doi.org/10.1186/1749-7922-9-37 .
doi: 10.1186/1749-7922-9-37
pubmed: 24883079
pmcid: 4039043
de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PH. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection. 2009;37(6):522–7. https://doi.org/10.1007/s15010-009-8249-6 .
doi: 10.1007/s15010-009-8249-6
pubmed: 19669089
Sandven P, Qvist H, Skovlund E, Giercksky KE, NORGAS Group, the Norwegian Yeast Study Group. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med. 2002;30(3):541–7. https://doi.org/10.1097/00003246-200203000-00008 .
Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34(3):646–52. https://doi.org/10.1097/01.CCM.0000201889.39443.D2 .
doi: 10.1097/01.CCM.0000201889.39443.D2
pubmed: 16505648
Klingspor L, Tortorano AM, Peman J, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006–2008). Clin Microbiol Infect. 2015;21(1):87e1–e10. https://doi.org/10.1016/j.cmi.2014.08.011 .
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1-50. https://doi.org/10.1093/cid/civ933 .
doi: 10.1093/cid/civ933
pubmed: 26679628
Chou EH, Mann S, Hsu TC, et al. Incidence, trends, and outcomes of infection sites among hospitalizations of sepsis: a nationwide study. PLoS ONE. 2020;15(1): e0227752. https://doi.org/10.1371/journal.pone.0227752 .
doi: 10.1371/journal.pone.0227752
pubmed: 31929577
pmcid: 6957188
Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med. 2003;31(3):752–7. https://doi.org/10.1097/01.CCM.0000053525.49267.77 .
doi: 10.1097/01.CCM.0000053525.49267.77
pubmed: 12626979
Dupont H, Guilbart M, Ntouba A, et al. Can yeast isolation be predicted in complicated secondary non-postoperative intra-abdominal infections? Crit Care. 2015;19:60. https://doi.org/10.1186/s13054-015-0790-3 .
doi: 10.1186/s13054-015-0790-3
pubmed: 25849844
pmcid: 4350296
Xia R, Wang D. Risk factors of invasive candidiasis in critical cancer patients after various gastrointestinal surgeries: a 4-year retrospective study. Medicine (Baltimore). 2019;98(44): e17704. https://doi.org/10.1097/MD.0000000000017704 .
doi: 10.1097/MD.0000000000017704
Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60(3):613–8. https://doi.org/10.1093/jac/dkm212 .
doi: 10.1093/jac/dkm212
pubmed: 17576697
Valerio M, Rodriguez-Gonzalez CG, Munoz P, et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother. 2014;69(7):1993–9. https://doi.org/10.1093/jac/dku053 .
doi: 10.1093/jac/dku053
pubmed: 24659750
Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015;41(9):1601–10. https://doi.org/10.1007/s00134-015-3866-2 .
doi: 10.1007/s00134-015-3866-2
pubmed: 26077063
Yan T, Li SL, Ou HL, Zhu SN, Huang L, Wang DX. Appropriate source control and antifungal therapy are associated with improved survival in critically ill surgical patients with intra-abdominal candidiasis. World J Surg. 2020. https://doi.org/10.1007/s00268-020-05380-x .
doi: 10.1007/s00268-020-05380-x
pubmed: 32328782
Bassetti M, Giacobbe DR, Vena A, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219. https://doi.org/10.1186/s13054-019-2497-3 .
doi: 10.1186/s13054-019-2497-3
pubmed: 31200780
pmcid: 6567430
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51. https://doi.org/10.1016/0895-4356(94)90129-5 .
doi: 10.1016/0895-4356(94)90129-5
pubmed: 7722560
Bassetti M, Marchetti M, Chakrabarti A, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med. 2013;39(12):2092–106. https://doi.org/10.1007/s00134-013-3109-3 .
doi: 10.1007/s00134-013-3109-3
pubmed: 24105327
Hosmer DW LS, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken: Wiley.
Sganga G, Wang M, Capparella MR, et al. Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies. Eur J Clin Microbiol Infect Dis. 2019;38(10):1849–56. https://doi.org/10.1007/s10096-019-03617-9 .
doi: 10.1007/s10096-019-03617-9
pubmed: 31280481
pmcid: 6778589
Bassetti M, Peghin M, Carnelutti A, et al. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Med. 2017;43(4):509–18. https://doi.org/10.1007/s00134-017-4717-0 .
doi: 10.1007/s00134-017-4717-0
pubmed: 28271321
Lagunes L, Rey-Perez A. What s new in intraabdominal candidiasis in critically ill patients, a review. Hosp Pract (1995). 2019;47(4):171–6. https://doi.org/10.1080/21548331.2019.1677032 .
Peman J, Aguilar G, Valia JC, et al. Javea consensus guidelines for the treatment of Candida peritonitis and other intra-abdominal fungal infections in non-neutropenic critically ill adult patients. Rev Iberoam Micol. 2017;34(3):130–42. https://doi.org/10.1016/j.riam.2016.12.001 .
doi: 10.1016/j.riam.2016.12.001
pubmed: 28579084
Munoz P, Agnelli C, Guinea J, et al. Is biofilm production a prognostic marker in adults with candidaemia? Clin Microbiol Infect. 2018;24(9):1010–5. https://doi.org/10.1016/j.cmi.2018.01.022 .
doi: 10.1016/j.cmi.2018.01.022
pubmed: 29408611
Munoz P, Vena A, Valerio M, et al. Risk factors for late recurrent candidaemia. A retrospective matched case-control study. Clin Microbiol Infect. 2016;22(3):277e11–20. https://doi.org/10.1016/j.cmi.2015.10.023 .
Jensen JU, Hein L, Lundgren B, et al. Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med. 2015;43(3):594–602. https://doi.org/10.1097/CCM.0000000000000746 .
doi: 10.1097/CCM.0000000000000746
pubmed: 25493970
Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51(5):e38-45. https://doi.org/10.1086/655698 .
doi: 10.1086/655698
pubmed: 20636126
Dudoignon E, Alanio A, Anstey J, et al. Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: a matched cohort study. Mycoses. 2019;62(3):237–46. https://doi.org/10.1111/myc.12872 .
doi: 10.1111/myc.12872
pubmed: 30478963
Rashid MU, Weintraub A, Nord CE. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe. 2012;18(2):249–53. https://doi.org/10.1016/j.anaerobe.2011.11.005 .
doi: 10.1016/j.anaerobe.2011.11.005
pubmed: 22155131
Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–28. https://doi.org/10.4161/viru.22913 .
doi: 10.4161/viru.22913
pubmed: 23302789
pmcid: 3654610
Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis. 1996;22(Suppl 2):S73-88. https://doi.org/10.1093/clinids/22.supplement_2.s73 .
doi: 10.1093/clinids/22.supplement_2.s73
pubmed: 8722833
Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27(6):1066–72. https://doi.org/10.1097/00003246-199906000-00019 .
doi: 10.1097/00003246-199906000-00019
pubmed: 10397206
Senn L, Eggimann P, Ksontini R, et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med. 2009;35(5):903–8. https://doi.org/10.1007/s00134-009-1405-8 .
doi: 10.1007/s00134-009-1405-8
pubmed: 19172247
Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219–26. https://doi.org/10.1093/cid/ciu074 .
doi: 10.1093/cid/ciu074
pubmed: 24550378
Vena A, Bouza E, Valerio M, et al. Candidemia in non-ICU surgical wards: comparison with medical wards. PLoS ONE. 2017;12(10): e0185339. https://doi.org/10.1371/journal.pone.0185339 .
doi: 10.1371/journal.pone.0185339
pubmed: 29045423
pmcid: 5646772
Molina J, Penalva G, Gil-Navarro MV, et al. Long-term impact of an educational antimicrobial stewardship program on hospital-acquired candidemia and multidrug-resistant bloodstream infections: a quasi-experimental study of interrupted time-series analysis. Clin Infect Dis. 2017;65(12):1992–9. https://doi.org/10.1093/cid/cix692 .
doi: 10.1093/cid/cix692
pubmed: 29020166
Martin-Gutierrez G, Penalva G, Ruiz-Perez de Pipaon M, et al. Efficacy and safety of a comprehensive educational antimicrobial stewardship program focused on antifungal use. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.01.002 .
Dimopoulos G, Matthaiou DK, Righi E, Merelli M, Bassetti M. Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. Minerva Anestesiol. 2017;83(11):1126–36. https://doi.org/10.23736/S0375-9393.17.11528-2 .
Vena A, Bouza E, Corisco R, et al. Efficacy of a “checklist” intervention bundle on the clinical outcome of patients with candida bloodstream infections: a quasi-experimental pre-post study. Infect Dis Ther. 2020. https://doi.org/10.1007/s40121-020-00281-x .
doi: 10.1007/s40121-020-00281-x
pubmed: 32632582
pmcid: 7452994
Cardozo C, Cuervo G, Salavert M, et al. An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia. J Antimicrob Chemother. 2019. https://doi.org/10.1093/jac/dkz491 .
doi: 10.1093/jac/dkz491
Vergidis P, Clancy CJ, Shields RK, et al. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS One. 2016;11(4): e0153247. https://doi.org/10.1371/journal.pone.0153247 .
doi: 10.1371/journal.pone.0153247
pubmed: 27123857
pmcid: 4849645